Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage

Abstract

Policy makers in countries, aiming to build and expand their healthcare systems and coverage, need effective procedures to support the most efficient use of limited financial resources. Tendering is commonly deployed to minimize and fix the purchasing price for the contract duration, especially for off-patent pharmaceuticals. While tenders can reduce acquisition costs, they may also expose the healthcare systems to risks including drug shortages, quality trade-offs, and ultimately, compromised patient health outcomes. Careful planning is therefore required. The effectiveness and impact of tendering were examined in different healthcare settings to establish good tender practices and to develop guidance for tender stakeholders in countries with expanding healthcare coverage for the effective conduct. The literature was reviewed for tender practices and outcomes in all countries, and tender experts from one multi-national pharmaceutical company in 17 countries with expanding healthcare coverage were surveyed on current tender practices. Tendering is a common practice for multisource pharmaceuticals in most countries worldwide. However, countries with expanding healthcare coverage specifically are vulnerable to the risks of defective tendering practices. Risk factors include non-transparent tender practices, a lack of consistency, unclear tender award criteria, a focus on lowest price only, single-winner tendering, and generally, a lack of impact monitoring. If well planned, managed, and conducted, tenders can be advantageous. Countries with expanding healthcare coverage should approach tenders strategically to achieve the desired improvements in healthcare. The good tender practices derived from this study may guide policy makers and purchasers in countries with expanding healthcare coverage on how to expand access to healthcare at an affordable cost. These include the use of multiple selection criteria and performance monitoring. Plain Language Summary Decision makers in countries aiming to expand their healthcare systems must best use the limited money available for healthcare. Tendering is commonly deployed for pharmaceuticals produced by multiple manufacturers (so-called multisource pharmaceuticals), to choose the product with the lowest price. Through tenders, purchasers request offers from suppliers for the needed products.The ultimate purpose of our research was to develop a guidance on robust tender processes. Therefore, we reviewed the literature to examine the effectiveness and impact of current tendering practices. In addition, we conducted a survey among tender experts from one pharmaceutical company in 17 countries with expanding healthcare coverage.In both the survey and the literature review, we confirmed that worldwide, tendering is a common practice for multisource pharmaceuticals. However, defective tendering practices may increase the vulnerability for some risks including abuse due to intransparent processes, lack of consistency, unclear tender award criteria, a focus on lowest price only, singl...

Determinants of drug prices: a systematic review of comparison studies

“…Conversely, because of this exact reason, too high tender frequency reduces competitive pressure. 42 Tiered pricing agreements have been successful in reducing drugs prices in developing countries multifold and are relatively easy to implement, although, within the scope of our study, we have not been able to collect additional proof of this. 28 All in all, no intervention should be evaluated on its own; new interventions need to be weighted in the total ecosystem of interventions.…”

Enhancing Learning Process using Double-Loop Theory in Purchasing Process of Healthcare Organization Toward Cutting Unnecessary Costs.

“…This makes pressures on most of the countries and make them strive toward to collected or universal healthcare coverage, to reach pocket spenders on private sections, but this will cause increased expenditures and put extra budget on public section. This will have bad impact on service level provided (Maniadakis, Holtorf, Otávio Corrêa, Gialama, & Wijaya, 2018). There is significant relationship between national expenditure on healthcare and gross domestic product (GDP) (Maniadakis et al, 2018).…”

“…This will have bad impact on service level provided (Maniadakis, Holtorf, Otávio Corrêa, Gialama, & Wijaya, 2018). There is significant relationship between national expenditure on healthcare and gross domestic product (GDP) (Maniadakis et al, 2018). If we take Saudi Arabia as example, we can see that the healthcare budgeting is increasing annually while the national income decreasing which is making huge burden (Fig 2).…”

Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China

“…Soaring pharmaceutical expenditure imposes a great burden on government budgets, which has triggered a range of policy, regulatory and managerial interventions. Collective purchasing has been used as a tool worldwide to lower the price of pharmaceutical supplies ( Dylst et al, 2011 ; Maniadakis et al, 2018 ). It forces suppliers to compete for the right to become a dominant supplier in certain markets in line with some strictly predefined criteria ( Maniadakis et al, 2018 ).…”

“…Collective purchasing has been used as a tool worldwide to lower the price of pharmaceutical supplies ( Dylst et al, 2011 ; Maniadakis et al, 2018 ). It forces suppliers to compete for the right to become a dominant supplier in certain markets in line with some strictly predefined criteria ( Maniadakis et al, 2018 ). A purchaser can increase its bargaining power by widening the network of collective purchasing.…”